Author Correction: Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis (Nature Communications, (2017), 8, 1, (1130), 10.1038/s41467-017-01236-6);Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Chakraborty, Debomita ^a   Šumová, Barbora ^a,b   Mallano, Tatjana ^a   Chen, Chih Wei ^a   Distler, Alfiya ^a   Bergmann, Christina ^a   Ludolph, Ingo ^a   Horch, Raymund E ^a   Gelse, Kolja ^a   Ramming, Andreas ^a   Distler, Oliver ^c   Schett, Georg ^a   Šenolt, Ladislav ^b   Distler, Jörg H W ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; JANUS KINASE 1; JANUS KINASE 2; SMALL INTERFERING RNA; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; BENZENESULFONIC ACID DERIVATIVE; BLEOMYCIN; COLLAGEN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; MOLECULAR ANALYSIS; PROTEIN; RODENT; SKIN DISORDER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADOLESCENT; ADULT; AGED; ANIMAL; BIOPSY; CHEMISTRY; CONFOCAL MICROSCOPY; ENZYME ACTIVATION; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; SKIN; SYSTEMIC SCLEROSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; ANIMALS; BENZENESULFONATES; BIOPSY; BLEOMYCIN; COLLAGEN; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; MALE; MICE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 85032222646     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-021-27450-x     Document Type: Erratum

References (67)

1. Wynn, T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
2. Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989-2003 (2009).
3. Varga, J. & Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557 (2007).
4. Massagué, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 (2012).
5. Verrecchia, F. & Mauviel, A. Transforming growth factor-β and fibrosis. World J. Gastroenterol. 13, 3056 (2007).
6. Leask, A. & Abraham, D. J. TGF-β signaling and the fibrotic response. FASEB J. 18, 816-827 (2004).
7. Kikuchi, K., et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-β1. J. Investig. Dermatol. 105, 128-132 (1995).
8. Sonnylal, S., et al. Postnatal induction of transforming growth factor β signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheumatol. 56, 334-344 (2007).
9. Massagué, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783-2810 (2005).
10. Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425, 577-584 (2003).
11. Zhang, Y. E. Non-Smad pathways in TGF-β signaling. Cell Res. 19, 128 (2009).
12. Daniels, C. E., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Investig. 114, 1308 (2004).
13. Akhmetshina, A., et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214-2222 (2008).
14. Varga, J. & Pasche, B. Anti-TGF-β therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr. Opin. Rheumatol. 20, 720 (2008).
15. Zhong, Z., Wen, Z. & Darnell, J. E. Jr Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95-99 (1994).
16. Song, L., Turkson, J., Karras, J. G., Jove, R. & Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150 (2003).
17. Yan, Y., et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 89, 68 (2016).
18. Kim, J.-H., et al. Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem. Pharmacol. 79, 373-380 (2010).
19. Garcia, R., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499 (2001).
20. Huang, G., Yan, H., Ye, S., Tong, C. & Ying, Q. L. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells 32, 1149-1160 (2014).
21. Sano, S., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11, 43 (2005).
22. Fagard, R., Metelev, V., Souissi, I. & Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2, e22882 (2013).
23. Furtek, S. L., Backos, D. S., Matheson, C. J. & Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 11, 308-318 (2016).
24. Yue, P. & Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs 18, 45-56 (2009).
25. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9, 798 (2009).
26. Chen, E., et al. A novel role of the STAT3 pathway in brain inflammationinduced human neural progenitor cell differentiation. Curr. Mol. Med. 13, 1474-1484 (2013).
27. Muangchant, C. & Pope, J. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systematic literature review. Clin. Exp. Rheumatol. 31, 122-134 (2012).
28. Ohkawara, B., et al. Role of the TAK1-NLK-STAT3 pathway in TGF-β-mediated mesoderm induction. Genes Dev. 18, 381-386 (2004).
29. Laklai, H., et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497-505 (2016).
30. Zhang, L., et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin. Cancer Res. 14, 559-568 (2008).
31. Siddiquee, K., et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA 104, 7391-7396 (2007).
32. Liu, Y., et al. Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J. Biol. Chem. 288, 30708-30719 (2013).
33. Uhl, M., et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961 (2004).
34. Reich, N., et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann. Rheum. Dis. 71, 737-745 (2012).
35. Skhirtladze, C., et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheumatol. 58, 1475-1484 (2008).
36. Tang, L.-Y., et al. Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway. J. Biol. Chem. 292, 4302-4312 (2017).
37. Zhang, Y., et al. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann. Rheum. Dis. 76, 1467-1475 (2017).
38. Pang, M., et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 78, 257-268 (2010).
39. Takeda, K., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94, 3801-3804 (1997).
40. Akira, S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17, 138-146 (1999).
41. Moinzadeh, P., et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J. Eur. Acad. Dermatol. Venereol. 26, 267-276 (2012).
42. Castro, S. V. & Jimenez, S. A. Biomarkers in systemic sclerosis. Biomark. Med. 4, 133-147 (2010).
43. Farina, G., Lafyatis, D., Lemaire, R. & Lafyatis, R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatology 62, 580-588 (2010).
44. Hasegawa, M. Biomarkers in systemic sclerosis: their potential to predict clinical courses. J. Dermatol. 43, 29-38 (2016).
45. Schmitt, N., et al. The cytokine TGF-β co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat. Immunol. 15, 856-865 (2014).
46. Xu, M.-Y., et al. Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis. Biochim. Biophys. Acta 1842, 2237-2245 (2014).
47. Chaudhry, A., et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986-991 (2009).
48. Liu, J., Chen, B., Lu, Y., Guan, Y. & Chen, F. JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure. Toxicol. Sci. 129, 363-371 (2012).
49. Wang, L., Kurosaki, T. & Corey, S. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway. Oncogene 26, 2851 (2007).
50. Dees, C., et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheumatol. 64, 3006-3015 (2012).
51. Wang, G., et al. STAT3 selectively interacts with Smad3 to antagonize TGF-β signaling. Oncogene 35, 4388 (2016).
52. Beyer, C., Schett, G., Distler, O. & Distler, J. H. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheumatol. 62, 2831-2844 (2010).
53. Andrés, R. M., Montesinos, M. C., Navalón, P., Payá, M. & Terencio, M. C. NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH. J. Investig. Dermatol. 133, 2362-2371 (2013).
54. Barnes, T. C., Anderson, M. E. & Moots, R. J. The many faces of interleukin-6: The role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int. J. Rheumatol. 2011, 721608 (2011).
55. Jacoby, J. J., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc. Natl Acad. Sci. USA 100, 12929-12934 (2003).
56. Shima, Y., et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 49, 2408-2412 (2010).
57. Milano, A., et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008).
58. Mueller, K. A., et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS ONE 10, e0126707 (2015).
59. Jin, J., Chou, C., Lima, M., Zhou, D. & Zhou, X. Systemic sclerosis is a complex disease associated mainly with immune regulatory and inflammatory genes. Open Rheumatol. J. 8, 29 (2014).
60. Elhai, M., et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res. 64, 1244-1249 (2012).
61. Li, C., et al. Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease. J. Immunol. 194, 3422-3431 (2015).
62. Miyoshi, K., et al. Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor. J. Investig. Dermatol. 131, 108-117 (2011).
63. Hoogen, F., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheumatol. 65, 2737-2747 (2013).
64. LeROY, E. C. & Medsger, T. A. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573-1576 (2001).
65. Palumbo-Zerr, K., et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-[beta] signaling and fibrosis. Nat. Med. 21, 150-158 (2015).
66. Akhmetshina, A., et al. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat. Commun. 3, 735 (2012).
67. Ruzehaji, N., et al. Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res. Ther. 17, 145 (2015).